Comparison of EBOV GP IgG Antibody Reactivity: Results from Two Immunoassays in the Democratic Republic of the Congo

By sjmartinez • April 8, 2025

Merritt S, Halbrook M, Kompany JP, Chandrasekaran P, Smith OA, Hoff NA, Tambu M, Martin SA, Wong TA, Jarra A, Barrall AL, Musene K, Beya M, Orr R, Myers T, MacGill T, Hensley LE, Muyembe-Tamfum JJ, Kaba D, Berry IM, Mbala-Kingebeni P, Lehrer AT, Rimoin AW. Comparison of EBOV GP IgG Antibody Reactivity: Results from Two Immunoassays in the Democratic Republic of the Congo. J Virol Methods. 2025 Apr 5:115154. doi: 10.1016/j.jviromet.2025.115154. Epub ahead of print. PMID: 40194662.

Tags: Democratic Republic of the Congo, EBOV GP, immunoassays, Infectious Diseases, Publications, serosurveillance

Factors associated with cervical cancer screening: results from cross-sectional surveys in Kenya and Malawi

Moucheraud C, Chibaka S, Golub G, Kalande P, Makwaya A, Ochieng E, Ogutu V, Phiri K, Phiri S, Hoffman RM. Factors associated with cervical cancer[...]

Risks for sudden cardiac and undetermined cause of death among people with HIV in the reprieve primary cardiovascular prevention trial

deFilippi C, Awwad A, Bloomfield GS, Weir IR, Ribaudo H, Zanni MV, Fichtenbaum CJ, Malvestutto CD, Aberg JA, Diggs MR, Chu SM, Paradis K, MacArthur[...]

rLVS(delta) capB/Yp F1-V single vector platform vaccine expressing Yersinia pestis F1 and LcrV antigens provides complete protection against lethal respiratory challenge with virulent plague bacilli

Jia Q, Bowen RA, Masleša-Galić S, Horwitz MA. rLVS ΔcapB/Yp F1-V single vector platform vaccine expressing Yersinia pestis F1 and LcrV antigens provides complete protection against lethal[...]